跳至主要内容
临床试验/NCT02002988
NCT02002988Unknown1 期

Endomyocardial Botulinum Toxin Injection Can Prevent Drug-Resistant Paroxysmal Atrial Fibrillation: Pilot Study

Meshalkin Research Institute of Pathology of Circulation2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2013年6月1日最近更新:
适应症

试验速览

阶段
1 期
发起方
入组人数
30
试验地点
2
主要终点
serious adverse events

研究概览

简要总结

The aim of this prospective non-randomized study was to assess the efficacy and safety of endomyocardial botulinum toxin injection in projections of main ganglionated plexuses of left atrium for preventing drug-resistant paroxysmal atrial fibrillation.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • drug-resistant PAF

排除标准

  • Previous heart surgery and AF ablation procedure
  • Emergency CABG
  • Unstable angina or heart failure
  • Persistent AF, AF at the time of screening (planned Maze procedure or pulmonary vein isolation)
  • Use of I or III antiarrhythmic drugs within 5 elimination half-lives of the drug (or within 2 months for amiodarone)
  • Requiring concomitant valve surgery
  • Left ventricle ejection fraction <35%
  • Left atrial diameter >55 mm
  • Unwillingness to participate

结局指标

主要结局

serious adverse events

时间窗: 1 year

次要结局

  • number of paroxysms(1 year)

研究者

发起方
Meshalkin Research Institute of Pathology of Circulation
申办方类型
Network
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Botulinum Toxin Injection Prevent Paroxysmal Atrial... | 临床试验